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Abstract: Thyroid cancer incidence is higher in World Trade Center (WTC) responders compared
with the general population. It is unclear whether this excess in thyroid cancer is associated with
WTC-related exposures or if instead there is an over-diagnosis of malignant thyroid cancer among
WTC first responders due to enhanced surveillance and physician bias. To maximize diagnostic yield
and determine the false positive rate for malignancy, the histological diagnoses of thyroid cancer
tumors from WTC responders and age, gender, and histology matched non-WTC thyroid cancer cases
were evaluated using biomarkers of malignancy. Using a highly accurate panel of four biomarkers that
are able to distinguish benign from malignant thyroid cancer, our results suggest that over-diagnosis
by virtue of misdiagnosis of a benign tumor as malignant does not explain the increased incidence of
thyroid cancer observed in WTC responders. Therefore, rather than over-diagnosis due to physician
bias, the yearly screening visits by the World Trade Center Health Program are identifying true cases
of thyroid cancer. Continuing regular screening of this cohort is thus warranted.
Keywords: 9/11; screening; thyroid cancer; biomarkers

1. Introduction
A significantly increased risk of thyroid cancer has been reported in the Mount Sinai Health
Program of World Trade Center (WTC) responders [1], WTC-exposed firefighters [2], and the New York
City Department of Health exposed residents [3], with an excess risk in the range of 2–3 times the
incidence reported by cancer registries.
The etiology behind this increased incidence of thyroid cancer remains unclear. Though multiple
carcinogens were identified at Ground Zero, including soot, benzene, and other volatile organic
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compounds from the burning of the jet fuel, in addition to the asbestos, silica, and other fibers that
were in the dust caused by the towers collapse, none are known to act as carcinogens on the thyroid [4].
Established risk factors for thyroid cancer, such as exposure to radiation or iodine-131, have not been
reported in connection to Ground Zero [5].
Instead, overdiagnosis as a consequence of surveillance and physician biases has been suggested as
a possible explanation of the excess risk of thyroid cancer in the WTC cohort [1]. Enhanced surveillance
leading to heightened diagnosis is a well-recognized phenomenon in heavily screened populations [6].
This phenomenon has been suggested as an explanation for other cancers for which WTC responders
have been observed to be at increased risk, such as prostate cancer [7]. Funded under the James
Zadroga 9/11 Health and Compensation Act of 2010, the World Trade Center Health Program (WTCHP)
monitors the health of WTC responders with yearly visits, including a physical examination, laboratory
testing, spirometry, and chest radiography. Chest imaging is known to increase detection of incidental
thyroid nodules [8], and WTC responders, many of whom report respiratory health problems [9], are
referred for imaging at higher rates, thus making the chance of discovery of a thyroid nodule more
likely. It is possible that some of these nodules would never have become clinically evident, and so
would have never been discovered, if not for this heightened screening [7].
Physician’s cognitive biases are known to lead to diagnostic inaccuracies [10]. Physicians treating
WTC responders, including pathologists, may suspect a worse diagnosis for these patients compared
with non-WTC responders due to implicit biases associated with knowledge of the patient’s past WTC
exposure. In addition, they may prefer risk aversion by a defensive diagnosing strategy to avoid
missing any malignancies and classify a suspicious nodule as cancerous [10]. This, along with the
increase in nodule detection due to enhanced screening through the WTCHP, may be leading to an
over-diagnosis of malignant thyroid cancer among WTC first responders.
The goal of this study is to analyze pathologists’ histological diagnosis of thyroid cancer in WTC
first responders and, by doing so, determine the false positive rate for malignancy. We will examine
the clinical characteristics and results of a cancer-detection four-biomarker panel of WTC tumors
compared with non-WTC exposed age-, gender-, and histology-matched cases.
2. Methods
2.1. Selection and Enrollment of Study Participants
Eligible WTC responders who participated (as employees or volunteers) in rescue, recovery,
and cleanup efforts at the WTC sites and who met established eligibility criteria [11] have been enrolled
in the WTCHP at Mount Sinai. Over 27,000 responders have had at least one monitoring visit in the
WTCHP and have consented to the aggregation of their data;20,984 of which have consented to have
their records used for medical research [12].
Cancer cases are identified through periodical linkage with the cancer registries of New York,
New Jersey, Pennsylvania, and Connecticut, as these states account for 98% of the responders’ residencies
at time of WTCHP enrollment. The full linkage methodology has been described elsewhere [1,12].
Only thyroid cancer cases validated by a cancer registry were eligible to participate in this study.
Additionally, WTC responders were only eligible if their enrollment in the WTCHP predated their
cancer diagnosis.
The full methodology used for patient recruitment and consent has been previously described [12].
In brief, eligible participants were contacted by phone, and those interested in participating were
mailed a consent form. After a patient’s consent, a cancer tissue sample was obtained from the
hospital where the patient’s thyroid surgery had taken place and clinical information related to their
cancer was abstracted from the pathology reports. For each patient, a pathologist reviewed the
tissue blocks to assure that cancer tissue was present, and 5 unstained slides of 4 µm thickness, in
addition to 1 hematoxylin and eosin (H/E) stained slide, were cut from the chosen formalin-fixed
paraffin-embedded (FFPE) tumor block. WTC cases were one-to-one matched by gender, histology,
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and age (+/- 5 years) to thyroid cancer samples obtained from the Mount Sinai Biorepository, with
no known WTC exposure. For cases with rare histology (n = 3), such as columnar cell papillary
carcinoma, it was not possible to match by histology, and matching was limited to age and gender.
After de-identification, all samples were sent to John Hopkins University for analysis. This study
protocol was approved by the Icahn School of Medicine at Mount Sinai’s Institutional Review Board
(IRB-17-01323).
2.2. Assessment of Clinical Characteristics
Pathology reports relating to the thyroid cancer surgeries of the WTC cases and Mount Sinai
non-WTC exposed controls were obtained, and data pertaining to the patient’s age, gender, tumor
histology, and size was abstracted into an excel database. To ensure that the WTC thyroid cancer cases
included in this study represented a random subset of the overall sample, characteristics of the study
sample were compared with the overall WTCHP thyroid cancer cohort using clinical data provided by
the WTCHP (Table 1).
Table 1. Characteristics of the study sample.
WTC Thyroid Cancer Cases

Non-WTC Controls

Clinical–Pathological Features

Eligible
(n = 43)

Included
(n = 30)

p Value a

Included
(n = 30)

p Value b

Age at Diagnosis (years)

48.5 (SD 7.7)

49.3 (SD 8.6)

0.65

47.8 (SD 11.3)

0.5652

Gender
Male
Female

0.16

1.00

36 (83.7%)
7 (16.3%)

21 (70%)
9 (30%)

27 (62.8%)

21 (70%)

21 (70%)

12 (27.9%)

6 (20%)

6 (20%)

4 (9.3%)

3 (10%)

3 (10%)

Tumor Size (cm)

1.38 (SD 1.16)

1.46 (SD 0.93)

0.78

Microcarcinoma
Yes c

14 (51.85%)

12 (40.0%)

0.37

Histology
Papillary thyroid carcinoma
Papillary thyroid carcinoma,
follicular variant
Other
c

21 (70%)
9 (30%)
0.74

1.00

a

Eligible versus included WTC thyroid cancer cases; b Included WTC versus non-WTC thyroid cancer cases; c Tumor
size unknown for 3 WTC cases; WTC: World Trade Center.

2.3. Immunohistochemistry Analysis
While diagnosis of papillary thyroid carcinoma (PTC), the most common subtype, can usually
be achieved through cytology, diagnosis of other thyroid cancer histologies can prove to be more
difficult [13], resulting in benign thyroid lesions being incorrectly classified as malignant. We have
previously developed a panel of molecular markers to distinguish benign from malignant thyroid
cancer, which can be used to cost-effectively identify the presence of over-diagnosis [14–16]. As seen
in Figure 1, the panel of molecular markers includes DDIT3, ITM1, C1orf24, and PVALB antibodies,
the utility of which has been described elsewhere [14–16], which can accurately discriminate between
malignant and benign tumors with a sensitivity and specificity close to 100% (Figure 1).
FFPE WTC and non-WTC thyroid tumor tissues were analyzed using these carcinoma markers.
Briefly, the FFPE sections (4 µm) were deparaffinized in xylene and rehydrated through a series
of graded alcohols. The endogenous alkaline phosphatase activity was blocked with 15% (vol/vol)
hydrogen peroxide in deionized water for 10 minutes. To expose the PVALB protein, permeabilization
was performed with 0.5% Tween in phosphate-buffered saline (PBS: 10 mM phosphate buffer, pH 7.2,
containing 0.15 M NaCl) at room temperature for 20 min. For PVALB and DDIT3, antigen retrieval was
performed using 0.1 M Tris-HCl for 15 min in a steamer. For C1orf24, antigen retrieval was performed
in a Tris-based solution pH 7.4 (AR-10; Biogenex Laboratories, San Ramon, CA) for 15 min in a pressure
cooker. For ITM1, antigen retrieval was performed using 0.1 M Tris-HCl pH 7.4 for 5 min in a pressure
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cooker. After antigen retrieval, the slides were allowed to cool down for 30 min. Non-specific binding
sites were blocked with 5% (C1orf24) or 10% (ITM1) normal goat serum 1 h or 5% bovine serum
albumin (BSA) (DDIT3 and PVALB) for 30 min prior to incubation with primary antibodies. Polyclonal
anti-C1orf24 and anti-ITM1 (custom produced) were used at 1:200 dilution. Monoclonal anti DDIT3
(Cat. 179823; Abcam, Cambridge) was used at 1:200 dilution, and anti-parvalbumin (clone PARV-19;
Cat. P3088, Sigma-Aldrich, St. Louis, MO) was used at 1:1000 dilution. For all antibodies, incubation
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tumor size (p = 0.77). Microcarcinomas, defined as thyroid cancer ≤1cm, were found in 52% of the
WTC thyroid cancer patients compared with 40% in the non-WTC thyroid cancer patients (Table 1).
2.4. Statistical Analysis
Antibody assessment correctly classified thyroid nodules in either group (Figure 2, Supplementary
Table S1).Continuous variables were summarized using mean ± standard deviation, whereas categorical
variables
summarized
as frequency
(%).tumor
Bivariate
hypothesis
conducted
using
Except forwere
three
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all thyroid
tissue
samples tests
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thyroid
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thetwotwo
sided
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Fisher’s
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groups and all histology types tested positive for malignancy with antibodies C1orf24, ITM1, and DDIT3
tests for categorical variables. All statistical analyses were performed using SAS 9.4 (SAS Institute
Inc., Cary, NC).
3. Results
There were 73 participants in the WTC cohort of responders who were eligible to be included
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no viable contact information. Of the remaining 69 WTC thyroid cancer patients, 37 patients (54%)
consented to participate. We were able to obtain FFPE thyroid tumor tissue samples for 30 WTC
participants. The comparison of the 30 WTC thyroid cancer patients who consented and the 43
Int. J. Environ. Res. Public Health 2019, 16, 1600
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gender, and histology; thus, it is expected that age and tumor size are similar between the two groups.
However, a descriptive study of the WTC thyroid cancer cases showed that these cases had similar
5
clinical characteristics as thyroid cancer cases in the Mount Sinai registry in terms of age at diagnosis
and tumor size, suggesting that surveillance bias alone cannot explain the excess risk of thyroid cancer
in WTC responders [17].
Being that the increased risk of thyroid cancer in WTC responders does not appear to be an
artifact due to physician bias, the results of this study leave open the possibility of an as-yet unknown
carcinogenic mechanism through which WTC exposure is acting on thyroid cancer carcinogenesis.
The biological basis of the tumors of WTC responders, including thyroid cancer tumors, warrants
further research.
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This is the first study to investigate the possible reasons for the increased incidence of thyroid
cancer in the WTC population and the first to show that over-diagnosis due to physician bias does not
appear to adequately explain the observed excess risk. The study is also novel in that it is the first to
utilize biomarkers of malignancy in a WTC cohort. A further strength of this study is the high rate of
compliance, with 54% of eligible WTC thyroid cancer patients agreeing to have their tumor sample
molecularly analyzed.
This study is limited in that not all tumor samples could be retrieved from the institutions where
the thyroid cancer surgery was performed and that, for a few samples, there was no tissue sample in
the slides provided. However, this was a small portion of the samples (5%). In addition, a comparison
of the characteristics of those patients for which we obtained a sample to the characteristics of the
eligible patients does not show any difference in personal or tumor characteristics, thus reducing the
possibility of selection bias.
Further analysis is needed to investigate a causal link between thyroid cancer in WTC-responders
and high levels of exposure to potentially carcinogenic agents at Ground Zero, which may result in
cancers with a shorter latency period, similar to that observed in individuals exposed to iodine-131
after the Chernobyl accident. It is well known that patients exposed to Chernobyl fallout demonstrated
a linear dose–response association. Therefore, to define whether there is a correlation between the
levels of exposure to the debris cloud and thyroid cancer, diagnosis is needed, as well as a longer
follow-up. [18]
Additionally, the investigation of somatic events that drive thyroid cancer pathogenesis in this
cohort, concomitant to longer follow-up and correlation with clinical-pathological features, will increase
our knowledge of whether the molecular events in WTC responders differ from those not exposed to
the dust cloud, as well as better define tumor aggressiveness [19,20].
5. Conclusions
In conclusion, rather than overdiagnosis of false-positives due to physician bias, it might instead
be the case that the yearly screening visits by the WTCHP are identifying true cases of thyroid
cancer earlier, increasing the possibility of a favorable prognosis, which warrants regular screening of
this cohort.
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